STAT3 and non-small cell lung carcinoma: Using the same cancer model, Zheng et al (168) investigated the novel STAT3 inhibitor, W2014-S, for its potential to enhance the efficacy of gefitinib and erlotinib in overcoming drug resistance in NSCLC.